Key Takeaways
- Conexeu Sciences is developing a regenerative breast matrix solution called B.R.E.A.S.T.
- The technology uses 3D printed extracellular matrix (ECM)-based biomaterials to support soft tissue regeneration.
- Conexeu is shifting the paradigm from substitution to restoration in breast reconstruction.
- The company is working under the CXU regenerative brand to develop the broader regenerative platform.
Introduction to Regenerative Breast Matrix Solutions
Conexeu Sciences is joining the likes of BellaSeno and Lattice Medical in the development of regenerative breast matrix solutions. These solutions aim to support soft tissue regeneration after breast reconstruction procedures. BellaSeno has been working on similar solutions since 2018 and has made significant progress, including starting clinical trials in 2022 and receiving authorization to offer products in Europe.
Comparison of Regenerative Breast Matrix Solutions
| Company | Solution | Technology | Status |
|---|---|---|---|
| Conexeu Sciences | B.R.E.A.S.T. | 3D printed ECM-based biomaterials | In development |
| BellaSeno | 3D printed PCL breast implants | 3D printing | Clinical trials |
| Lattice Medical | Osteoconductive lattice structures | 3D printing | Available in Europe |
Conexeu's B.R.E.A.S.T. Platform
Conexeu's B.R.E.A.S.T. platform is designed to support soft tissue regeneration after breast reconstruction procedures. The technology uses 3D printed extracellular matrix (ECM)-based biomaterials to create a bio-regenerative solution. According to Conexeu CEO Miles D. Harrison, the company is shifting the paradigm from substitution to restoration in breast reconstruction. The B.R.E.A.S.T. platform is being developed under the CXU regenerative brand.
Market Potential
The market potential for regenerative breast matrix solutions is significant. With over 1.7 million breast reconstruction procedures performed worldwide in 2020, the demand for innovative solutions is high. Conexeu's B.R.E.A.S.T. platform has the potential to capture a significant share of this market, with its unique technology and approach to breast reconstruction.
Bottom Line
Conexeu Sciences is making significant strides in the development of regenerative breast matrix solutions with its B.R.E.A.S.T. platform. With its unique technology and approach to breast reconstruction, the company has the potential to capture a significant share of the market. As the field of regenerative medicine continues to evolve, Conexeu is well-positioned to be a leader in the development of innovative solutions for breast reconstruction. With a strong focus on research and development, Conexeu is expected to make significant progress in the coming years, and its B.R.E.A.S.T. platform is likely to be a major contributor to this success.